{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:03:24Z","timestamp":1789506204636,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113-2320-B-182-005-"],"award-info":[{"award-number":["NSTC 113-2320-B-182-005-"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004725","name":"Ministry of Economic Affairs ROC","doi-asserted-by":"publisher","award":["MOEA 112-EC-17-A-22-1651"],"award-info":[{"award-number":["MOEA 112-EC-17-A-22-1651"]}],"id":[{"id":"10.13039\/501100004725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neo.2025.101253","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:42:11Z","timestamp":1763340131000},"page":"101253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancer"],"prefix":"10.1016","volume":"71","author":[{"given":"Chiu-Lien","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ning","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsan-Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Ru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Keng","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsan-Lin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsun-Hao","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2334-0302","authenticated-orcid":false,"given":"Chih-Wei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Hsuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chih","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8245-4302","authenticated-orcid":false,"given":"Po-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"See-Tong","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Ho","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1413-817X","authenticated-orcid":false,"given":"Ling-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2025.101253_bib0001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11912-017-0568-7","article-title":"Mechanisms of therapeutic resistance in","volume":"19","author":"Nakazawa","year":"2017","journal-title":"Prostate Cancer Curr. Oncol. Rep."},{"key":"10.1016\/j.neo.2025.101253_bib0002","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41419-022-05084-1","article-title":"Second generation androgen receptor antagonists and challenges in prostate cancer treatment","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neo.2025.101253_bib0003","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2025.101253_bib0004","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0140","article-title":"Androgen receptor mutations for precision medicine in prostate cancer","volume":"29","author":"Shiota","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.neo.2025.101253_bib0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.150","article-title":"Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer: experience from a safety-net hospital serving a racially and ethnically diverse patient population","volume":"41","author":"Liang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101253_bib0006","doi-asserted-by":"crossref","unstructured":"Zhao J., Ning S., Lou W., Yang J.C., Armstrong C.M., Lombard A.P., D'Abronzo L.S., Evans C.P., Gao A.C., Liu C. (2020). Cross-resistance among next-generation antiandrogen drugs through the AKR1C3\/AR-V7 axis in advanced prostate cancer molecular cancer therapeutics 19, 1708-1718.","DOI":"10.1158\/1535-7163.MCT-20-0015"},{"key":"10.1016\/j.neo.2025.101253_bib0007","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.neo.2025.101253_bib0008","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone","volume":"35","author":"Antonarakis","year":"2017","journal-title":"Enzalutamide J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101253_bib0009","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.neo.2025.101253_bib0010","doi-asserted-by":"crossref","unstructured":"Guo Z., Yang X., Sun F., Jiang R., Linn D.E., Chen H., Chen H., Kong X., Melamed J., Tepper C.G., et al. (2009). A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth cancer research 69, 2305-2313.","DOI":"10.1158\/0008-5472.CAN-08-3795"},{"key":"10.1016\/j.neo.2025.101253_bib0011","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","article-title":"Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines","volume":"73","author":"Li","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101253_bib0012","doi-asserted-by":"crossref","unstructured":"Antonarakis E.S., Armstrong A.J., Dehm S.M., Luo J. (2016). Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting prostate cancer and prostatic diseases 19, 231-241.","DOI":"10.1038\/pcan.2016.17"},{"key":"10.1016\/j.neo.2025.101253_bib0013","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.177","article-title":"Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer","volume":"41","author":"Pachynski","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101253_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5111","article-title":"A phase 1\/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer","volume":"42","author":"Yu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101253_bib0015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neo.2025.101253_bib0016","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev-pharmtox-030624-110238","article-title":"PROTACs as therapeutic modalities for drug discovery in castration-resistant prostate","volume":"65","author":"Wang","year":"2025","journal-title":"Cancer Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neo.2025.101253_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104500","article-title":"Targeting androgen receptor and the variants by an orally bioavailable proteolysis Targeting Chimeras compound in castration resistant prostate cancer","volume":"90","author":"Hung","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neo.2025.101253_bib0018","doi-asserted-by":"crossref","unstructured":"Wang J., Qian M., Yan P., Li L., Zhang C., Yu Y., Tao L., Tang P., Liao Y., Chen X., et al. (2023). Abstract LB262: HSK38008: an oral AR-V7 degrader for metastatic castration-resistant prostate cancer cancer research 83, LB262-LB262.","DOI":"10.1158\/1538-7445.AM2023-LB262"},{"key":"10.1016\/j.neo.2025.101253_bib0019","doi-asserted-by":"crossref","unstructured":"Lee G.T., Nagaya N., Desantis J., Madura K., Sabaawy H.E., Kim W.J., Vaz R.J., Cruciani G., Kim I.Y. (2021). Effects of MTX-23, a novel PROTAC of androgen receptor splice variant-7 and androgen receptor, on CRPC resistant to second-line antiandrogen therapy molecular cancer therapeutics 20, 490-499.","DOI":"10.1158\/1535-7163.MCT-20-0417"},{"key":"10.1016\/j.neo.2025.101253_bib0020","doi-asserted-by":"crossref","unstructured":"Ma B., Fan Y., Zhang D., Wei Y., Jian Y., Liu D., Wang Z., Gao Y., Ma J., Chen Y., et al. (2022). De Novo design of an androgen receptor DNA binding domain-targeted peptide PROTAC for Prostate cancer therapy Adv Sci (Weinh) 9, e2201859.","DOI":"10.1002\/advs.202201859"},{"key":"10.1016\/j.neo.2025.101253_bib0021","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/pros.23251","article-title":"High-content screening identifies Src Family kinases as potential regulators of AR-V7 expression and androgen-independent","volume":"77","author":"Szafran","year":"2017","journal-title":"Cell Growth Prostate"},{"key":"10.1016\/j.neo.2025.101253_bib0022","doi-asserted-by":"crossref","first-page":"10529","DOI":"10.1128\/MCB.24.24.10529-10541.2004","article-title":"Negative modulation of androgen receptor transcriptional activity by","volume":"24","author":"Lin","year":"2004","journal-title":"Daxx Mol. Cell Biol."},{"key":"10.1016\/j.neo.2025.101253_bib0023","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12964-024-02010-0","article-title":"Targeting the ERK1\/2 and p38 MAPK pathways attenuates Golgi tethering factor golgin-97 depletion-induced cancer progression in breast cancer","volume":"23","author":"Liu","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.neo.2025.101253_bib0024","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1021\/ci100241y","article-title":"Analyzing the topology of active sites: on the prediction of pockets and subpockets","volume":"50","author":"Volkamer","year":"2010","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.neo.2025.101253_bib0025","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1021\/ci200454v","article-title":"Combining global and local measures for structure-based druggability predictions","volume":"52","author":"Volkamer","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.neo.2025.101253_bib0026","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.neo.2025.101253_bib0027","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1073\/pnas.081565498","article-title":"Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone","volume":"98","author":"Sack","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neo.2025.101253_bib0028","doi-asserted-by":"crossref","first-page":"18550","DOI":"10.18632\/oncotarget.14537","article-title":"Androgen receptor splice variants and prostate cancer: from bench to bedside","volume":"8","author":"Wadosky","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2025.101253_bib0029","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/humu.21138","article-title":"Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line","volume":"31","author":"Marcias","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.neo.2025.101253_bib0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.neo.2025.101253_bib0031","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neo.2025.101253_bib0032","doi-asserted-by":"crossref","first-page":"R146","DOI":"10.1530\/EC-17-0118","article-title":"Clinical relevance of androgen receptor alterations in prostate cancer","volume":"6","author":"Jernberg","year":"2017","journal-title":"Endocr. Connect"},{"key":"10.1016\/j.neo.2025.101253_bib0033","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.204","article-title":"Real-world assessment of AR-LBD mutations in metastatic castration-resistant prostate cancer","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101253_bib0034","article-title":"A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant","volume":"13","author":"Miller","year":"2023","journal-title":"Prostate Cancer Front. Oncol."},{"key":"10.1016\/j.neo.2025.101253_bib0035","article-title":"Androgen receptor promotes ligand-independent prostate cancer progression through c-myc upregulation","volume":"8","author":"Gao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neo.2025.101253_bib0036","article-title":"Androgen receptor signaling and metabolic and cellular plasticity during progression to castration resistant","volume":"10","author":"Uo","year":"2020","journal-title":"Prostate Cancer Front. Oncol."},{"key":"10.1016\/j.neo.2025.101253_bib0037","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1200\/JCO.2008.17.2882","article-title":"Genomic strategy for targeting therapy in castration-resistant prostate cancer","volume":"27","author":"Mendiratta","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101253_bib0038","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1038\/s41598-022-09371-x","article-title":"Cistrome and transcriptome analysis identifies unique androgen receptor (AR) and AR-V7 splice variant chromatin binding and transcriptional activities","volume":"12","author":"Basil","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neo.2025.101253_bib0039","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15398","article-title":"pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase","volume":"8","author":"An","year":"2017","journal-title":"Nat Commun."},{"key":"10.1016\/j.neo.2025.101253_bib0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kronke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.neo.2025.101253_bib0041","article-title":"Abstract 43: discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101253_bib0042","first-page":"3198","article-title":"Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer clinical cancer research : an official journal of the","volume":"20","author":"Liu","year":"2014","journal-title":"Am. Assoc. Cancer Res."},{"key":"10.1016\/j.neo.2025.101253_bib0043","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41388-022-02566-6","article-title":"Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer","volume":"42","author":"Yang","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2025.101253_bib0044","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101253_bib0045","first-page":"1413","article-title":"Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide","volume":"75","author":"Liu","year":"2015","journal-title":"Prostate Cancer Cancer Res."},{"key":"10.1016\/j.neo.2025.101253_bib0046","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1535-7163.MCT-16-0186","article-title":"Inhibition of AKR1C3 activation overcomes resistance to abiraterone in advanced prostate","volume":"16","author":"Liu","year":"2017","journal-title":"Cancer Mol. Cancer Ther."},{"key":"10.1016\/j.neo.2025.101253_bib0047","first-page":"273","article-title":"Current strategies for the design of PROTAC linkers: a critical review explor","volume":"1","author":"Troup","year":"2020","journal-title":"Target Antitumor. Ther."},{"key":"10.1016\/j.neo.2025.101253_bib0048","first-page":"88","article-title":"A beginner's guide to current synthetic linker strategies towards VHL-recruiting","author":"Zografou-Barredo","year":"2023","journal-title":"PROTACs Bioorg. Med. Chem."},{"key":"10.1016\/j.neo.2025.101253_bib0049","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.apsb.2024.04.007","article-title":"Characteristic roadmap of linker governs the rational design of PROTACs","volume":"14","author":"Dong","year":"2024","journal-title":"Acta Pharm. Sin B"},{"key":"10.1016\/j.neo.2025.101253_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115793","article-title":"Current advances and development strategies of orally bioavailable PROTACs","volume":"261","author":"Zeng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neo.2025.101253_bib0051","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/ijc.31818","article-title":"Interference with the androgen receptor protein stability in therapy-resistant prostate cancer","volume":"144","author":"Lakshmana","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.neo.2025.101253_bib0052","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/ijc.32242","article-title":"Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models","volume":"145","author":"Sugawara","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.neo.2025.101253_bib0053","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-11-3892","article-title":"Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101253_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100276","article-title":"Androgen receptor splicing variant 7 (ARV7) inhibits docetaxel sensitivity by inactivating the spindle assembly checkpoint","volume":"296","author":"Yu","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neo.2025.101253_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2024.114026","article-title":"AR-V7 expression facilitates accelerated G2\/M phase transition in castration-resistant prostate cancer","volume":"438","author":"Saini","year":"2024","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.neo.2025.101253_bib0056","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1535-7163.MCT-18-1322","article-title":"AKR1C3 Promotes AR-V7 protein stabilization and confers resistance to AR-targeted therapies","volume":"18","author":"Liu","year":"2019","journal-title":"Adv. Prostate Cancer Mol. Cancer Ther."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625001332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625001332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:17:43Z","timestamp":1765556263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558625001332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"alternative-id":["S1476558625001332"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2025.101253","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2025.101253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101253"}}